{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:08:45Z","timestamp":1792058925377,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.antiviral.2026.106352","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:43:26Z","timestamp":1769759006000},"page":"106352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations"],"prefix":"10.1016","volume":"248","author":[{"given":"Irina","family":"Yurgelonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-429X","authenticated-orcid":false,"given":"Zhenghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8369-021X","authenticated-orcid":false,"given":"Patricia","family":"McMonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-2575","authenticated-orcid":false,"given":"Stephen","family":"Noell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Plotnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-2991","authenticated-orcid":false,"given":"Jennifer","family":"Nicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-444X","authenticated-orcid":false,"given":"Timothy K.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-7828","authenticated-orcid":false,"given":"Elizabeth","family":"Titova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Behzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussin","family":"Rothan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-6836","authenticated-orcid":false,"given":"Yuao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry N.","family":"Kreiswirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda D.","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.N.","family":"Allerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106352_bib1","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106352_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105819","article-title":"Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19","volume":"118","author":"Baniecki","year":"2025","journal-title":"EBioMedicine."},{"key":"10.1016\/j.antiviral.2026.106352_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e41980","article-title":"SARS-CoV-2 drug resistance and therapeutic approaches","volume":"11","author":"Batool","year":"2025","journal-title":"Heliyon."},{"key":"10.1016\/j.antiviral.2026.106352_bib5","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1021\/jacsau.4c00508","article-title":"A structural comparison of oral SARS-CoV-2 drug candidate ibuzatrelvir complexed with the main protease (Mpro) of SARS-CoV-2 and MERS-CoV","volume":"4","author":"Chen","year":"2024","journal-title":"JACS Au."},{"key":"10.1016\/j.antiviral.2026.106352_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/v17050722","article-title":"Evolution of antiviral drug resistance in SARS-CoV-2","volume":"17","author":"Dinata","year":"2025","journal-title":"Viruses."},{"key":"10.1016\/j.antiviral.2026.106352_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature."},{"key":"10.1016\/j.antiviral.2026.106352_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02624-24","article-title":"Structural basis for varying drug resistance of SARS-CoV-2 mpro E166 variants","author":"Esler","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2026.106352_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106352_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1208\/s12248-023-00832-3","article-title":"Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir","volume":"25","author":"Gerhart","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.antiviral.2026.106352_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2026.106352_bib13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2026.106352_bib14","volume":"121","author":"Hattori","year":"2024"},{"key":"10.1016\/j.antiviral.2026.106352_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: the dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics."},{"key":"10.1016\/j.antiviral.2026.106352_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature."},{"key":"10.1016\/j.antiviral.2026.106352_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106118","article-title":"M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings","volume":"236","author":"Inoue","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"EBioMedicine."},{"key":"10.1016\/j.antiviral.2026.106352_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106352_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02815-22","article-title":"The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir","volume":"14","author":"Jochmans","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2026.106352_bib21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly."},{"key":"10.1016\/j.antiviral.2026.106352_bib22","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1038\/s41467-023-40018-1","article-title":"In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir","volume":"14","author":"Kiso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106352_bib23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.str.2023.06.010","article-title":"Structural basis for the inhibition of coronaviral main proteases by ensitrelvir","volume":"31","author":"Lin","year":"2023","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2026.106352_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s42003-023-05071-y","article-title":"Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants","volume":"6","author":"Lin","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.antiviral.2026.106352_bib25","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The lancet."},{"key":"10.1016\/j.antiviral.2026.106352_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2026.106352_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s44259-023-00009-0","article-title":"Rapid resistance profiling of SARS-CoV-2 protease inhibitors","volume":"1","author":"Moghadasi","year":"2023","journal-title":"npj Antimicrobials. Resistance."},{"key":"10.1016\/j.antiviral.2026.106352_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic response and safety of ibuzatrelvir, A novel SARS-CoV-2 antiviral, in adults with COVID-19","volume":"80","author":"Mortezavi","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106352_bib30","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01031-17","article-title":"Complexities of viral mutation rates","volume":"92","author":"Peck","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2026.106352_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature."},{"key":"10.1016\/j.antiviral.2026.106352_bib33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib35","series-title":"A Simple Method of Estimating Fifty per Cent Endpoints","author":"Reed","year":"1938"},{"key":"10.1016\/j.antiviral.2026.106352_bib36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","article-title":"The P132H mutation in the main protease of omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition","volume":"32","author":"Sacco","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib37","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106352_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virs.2022.01.029","article-title":"The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro","volume":"37","author":"Sonnleitner","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.antiviral.2026.106352_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.antiviral.2026.106352_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","article-title":"SARS-CoV-2 main protease drug design, assay development, and drug resistance studies","volume":"56","author":"Tan","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib41","article-title":"Evasion of T cell responses by newly emerging SARS-CoV-2 variants","volume":"3","author":"Tian","year":"2025","journal-title":"Nature Portfolio Heidelberger Platz."},{"key":"10.1016\/j.antiviral.2026.106352_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2026.106352_bib43","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106352_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib45","series-title":"Targeted Protein Degraders of SARS-CoV-2 Mpro Demonstrate Superior Antiviral Activity over Enzymatic Inhibition Alone and Potency Against Nirmatrelvir Resistant Virus","author":"Warner","year":"2024"},{"key":"10.1016\/j.antiviral.2026.106352_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/acsbiomedchemau.4c00045","article-title":"An investigation of nirmatrelvir (paxlovid) resistance in SARS-CoV-2 mpro","volume":"4","author":"Yaghi","year":"2024","journal-title":"ACS bio med Chem Au."},{"key":"10.1016\/j.antiviral.2026.106352_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Sci."},{"key":"10.1016\/j.antiviral.2026.106352_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41421-024-00673-0","article-title":"Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell discovery"},{"key":"10.1016\/j.antiviral.2026.106352_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/acs.jproteome.0c00526","article-title":"Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication","volume":"20","author":"Zhang","year":"2020","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105429","article-title":"Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study","volume":"208","author":"Zhu","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106352_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:44:28Z","timestamp":1781685868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S0166354226000112"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106352","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Pfizer Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106352"}}